Emma Plested
Programme and Regulatory Affairs Director (UK)
Emma Plested is a Programme and Regulatory Affairs Director (UK) for the Oxford Vaccine Group (OVG). Emma joined the group in January 2005 and is responsible for the oversight of the full UK portfolio of trials undertaken by OVG. Emma leads the Project Management team who are responsible for ensuring all projects are delivered on time, within budget and in compliance with regulatory requirements.
Recent publications
-
The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study.
Maytum A. et al, (2024), Pediatr Infect Dis J
-
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents.
Ratcliffe H. et al, (2023), iScience, 26
-
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209
-
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Shaw RH. et al, (2022), Lancet Respir Med, 10, 1049 - 1060
-
Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019-2021.
Ratcliffe H. et al, (2022), Arch Dis Child